GeneDx (NASDAQ: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest rare disease data sets.